Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B

Novo Nordisk (NYSE:NVO) is one of the stocks that should double in 3 years. On February 4, Novo Nordisk delivered 10% sales growth in 2025, driven by its obesity and diabetes portfolios. The company’s obesity care sales reached DKK 82 billion, marking a substantial increase since 2019 and expanding its reach to 16 million additional patients. Financial results surpassed expectations with a reported EPS of $1, although the gross margin decreased to 81% due to manufacturing acquisitions and restructuring costs.

The year was highlighted by major regulatory and pipeline milestones, including the FDA approval and successful launch of the Wegovy pill, the first oral GLP-1 for weight management. Clinical data for CagriSema showed superior weight loss and glycemic control compared to semaglutide, and the company is progressing with its next-gen treatment, zenagamtide. Additionally, Novo Nordisk is expanding its focus into rare diseases and cardiovascular comorbidities, with several Phase III readouts and regulatory decisions anticipated throughout 2026.

Leadership transitions were also confirmed, with Jamey Millar and Hong Chow joining the executive team as several long-standing leaders depart. For 2026, Novo Nordisk (NYSE:NVO) issued a cautious financial outlook, projecting an adjusted sales and operating profit decline of 5% to 13% at constant exchange rates. This forecast accounts for significant pricing headwinds in the US and patent expirations in international markets, though the company remains focused on volume growth and long-term strategic aspirations to be unveiled at its upcoming Capital Markets Day.

Pixabay/Public Domain

Novo Nordisk (NYSE:NVO) together with its subsidiaries, engages in the R&D, manufacture, and distribution of pharmaceutical products. It has two segments: Obesity & Diabetes Care and Rare Disease.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.